Health Topics — Stress & Anxiety
Why Anxiety Lives in the Body, Not Just the Mind
For the person whose anxiety shows up as a tight chest, a shallow breath, or a stomach that won't settle before the worried thoughts even arrive.
Sometimes the anxiety arrives in your chest before you've had a thought about anything. The tightening. The shallow breath. The stomach that drops for no reason you can name. The body is already in it before the mind catches up to ask why.
If you've tried to think your way out of anxiety and found that the thinking is the last part to help — this is why. Anxiety is not primarily a thought problem. It is a body problem that eventually becomes a thought problem. Understanding the order of operations changes what you look for.
Anxiety is the nervous system responding to perceived threat. That response was designed for physical danger — it mobilizes the body to fight or flee. The heart rate climbs. The breathing shallows. Blood moves away from the digestive system toward the muscles. The muscles tense. The senses sharpen. This is not a malfunction. It is a system working exactly as it was designed to work, in a context where the threat it is responding to is not a predator but a meeting, a relationship, a future, a body that has been carrying unresolved stress for too long.
The problem is not the anxiety response. The problem is an anxiety response that will not turn off. A nervous system that reads the environment as threatening even when no threat is present. A body that stays in low-level alert because it has learned, through experience, that dropping its guard tends to be followed by something requiring the guard again.
This is the body's anxiety, not the mind's. The thoughts that accompany it — the catastrophizing, the rumination, the imagined outcomes — are the mind trying to make sense of a body that is already activated. Addressing the thoughts without addressing the body state that produced them is working in the wrong order.
What's actually happening in the nervous system
The amygdala — a small structure in the brain that functions as a threat-detection center — processes sensory information faster than the conscious, reasoning parts of the brain can. It doesn't wait for you to evaluate whether something is dangerous. It responds first and lets the thinking catch up. This is why the body is already in the anxiety response before you've had a thought about why.
The endocannabinoid system is present throughout the brain circuits involved in this process. CB1 receptors are expressed in the amygdala, in the prefrontal cortex that regulates the amygdala's response, and in the hippocampus that provides context for determining whether a threat is real. The endocannabinoid system doesn't initiate the threat response — it modulates it. Its job, in part, is to help the prefrontal cortex reassert regulation after the amygdala has fired. To turn down the alarm once the threat has passed, or been assessed and found manageable.
When endocannabinoid tone is low — depleted by chronic stress, poor sleep, or sustained activation of the threat system — that regulatory capacity is reduced. The amygdala fires more readily and recovers more slowly. The body stays in the anxious state longer than it needs to, and the threshold for triggering the response again drops. This is how anxiety becomes a pattern rather than a response.
What the research on CBD and CBG has examined
CBD has the most extensive human anxiety research of any cannabinoid. Multiple controlled trials have found significant anxiety reduction compared to placebo — most notably in social anxiety, where the research is most developed. CBD's primary relevant mechanism is FAAH inhibition: it slows the breakdown of anandamide, the body's own endocannabinoid, supporting its availability in the circuits where regulation is needed. It also interacts with 5-HT1A serotonin receptors — the same receptors targeted by some anxiety medications — in a way that may contribute to its anxiolytic effects in some research populations.
CBG's most relevant anxiety research is the 2024 Cuttler randomized controlled trial — the first human study of CBG's acute effects. Thirty-four adults received a single 20mg oral CBG dose in a double-blind, placebo-controlled crossover design. Self-reported anxiety and stress were measurably lower at all three measurement points compared to placebo. No intoxication was reported. Cognitive function remained stable. This is a meaningful first signal from a well-designed study in healthy adults.
CBG's mechanism in this context involves the alpha-2 adrenoceptor — a receptor that regulates norepinephrine, the primary chemical of arousal and acute stress. By acting on this receptor, CBG may reduce the norepinephrine signal that underlies the physical symptoms of anxiety: the racing heart, the tightened chest, the shallow breath. This is the body's anxiety — and this is where CBG's mechanism is most directly relevant to it.
On anxiety and clinical care
Anxiety disorders are diagnosed conditions that benefit from clinical assessment and evidence-based treatment — including therapy and, where appropriate, medication. The research described here is relevant context, not a treatment recommendation.
The human research on CBD and anxiety is meaningful but limited in scale and population. CBG's human anxiety research consists of one trial in healthy adults. We present both in that proportion.
What this means in practice
We can't tell you that a CBG or CBD preparation will resolve your anxiety. What we can offer is the biological picture — the nervous system architecture that underlies physical anxiety symptoms, and the mechanisms through which cannabinoids interact with that architecture — so that if you are considering whether a whole-plant preparation is worth trying, you have a grounded context rather than marketing language.
If the anxiety arrives in your body before your mind catches up, the most relevant question isn't "what should I think differently" — it's "what does the body need to stand down." The endocannabinoid system is part of that biology. Consistent support for that system over time is more aligned with how regulatory capacity is restored than acute intervention at moments of peak anxiety.
Future articles in this pillar examine specific anxiety research in more detail — the social anxiety CBD trials, CBG's alpha-2 mechanism in full, and the relationship between anxiety and sleep that makes the two so difficult to address separately. The research section is the place to start if you want the fuller picture now.
Anxiety in the body before the mind is not irrationality — it is the nervous system doing exactly what it was built to do, in a context that activates it too readily and resolves it too slowly. The endocannabinoid system is part of the regulatory architecture that governs that resolution. The research on CBD and CBG in this context is real, developing, and worth understanding honestly. We will follow it and update this article as the evidence grows.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.